Drugs.com Clinical Trial ResultsOriginal article
Novo Nordisk STEP Young Phase 3 Data: 40.4% of Children Living with Obesity Achieved a BMI Below the Obesity Threshold with Semaglutide and Lifestyle Modification
Phase 3positivesemaglutidePositive
AI Analysis
Summary
Novo Nordisk announced positive Phase 3 STEP Young trial results showing 40.4% of children with obesity achieved a BMI below the obesity threshold with once-weekly semaglutide combined with lifestyle modification.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
40.4% of children achieved a BMI below the obesity threshold with semaglutide and lifestyle modification
Importance:7/10
Sentiment:
0.75
phase 3 datapediatric obesitysemaglutideSTEP Young trialpositive results
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 7, 2026 9:09 PM